China's Health Reform Will Nurture New Drugs, And Boost Use Of Old Ones
Executive Summary
In addition to dramatically increasing access to mainly generic drugs, China's sweeping and upcoming health reform will also include measures designed to spur R&D, according to Song Ruilin, executive director-general at the Chinese Pharmaceutical Association's Research Center for Medicinal Policy